Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2020

March 2020 | 250 pages | ID: I90BA505FC4EN
Global Markets Direct

Abstracts

Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2020, provides an overview of the Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline landscape.

H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by a contagious virus. H1N1 flu infects the breathing tubes in nose, throat, and lungs. The disease is contagious. When people who have it cough or sneeze, they spray tiny drops of the virus into the air. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache and fatigue. Treatment includes medication (antiviral drugs).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 7, 9, 4, 43, 7 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 4, 2, 13 and 2 molecules, respectively.

Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Influenza A Virus, H1N1 Subtype Infections - Overview
Influenza A Virus, H1N1 Subtype Infections - Therapeutics Development
Influenza A Virus, H1N1 Subtype Infections - Therapeutics Assessment
Influenza A Virus, H1N1 Subtype Infections - Companies Involved in Therapeutics Development
Influenza A Virus, H1N1 Subtype Infections - Drug Profiles
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects
Influenza A Virus, H1N1 Subtype Infections - Discontinued Products
Influenza A Virus, H1N1 Subtype Infections - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Influenza A Virus, H1N1 Subtype Infections - Pipeline by AbbVie Inc, H1 2020
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Abzyme Therapeutics LLC, H1 2020
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Adimmune Corp, H1 2020
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H1 2020
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Alla Chem LLC, H1 2020
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Allergy Therapeutics Plc, H1 2020
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Altimmune Inc, H1 2020
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H1 2020
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H1 2020 (Contd..2), H1 2020
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H1 2020 (Contd..3), H1 2020
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H1 2020 (Contd..4), H1 2020
Influenza A Virus, H1N1 Subtype Infections - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

AbbVie Inc
Abzyme Therapeutics LLC
Adimmune Corp
Akshaya Bio Inc
Alla Chem LLC
Allergy Therapeutics Plc
Altimmune Inc
Ansun Biopharma Inc
Asavi Llc
AstraZeneca Plc
Beijing Minhai Biotechnology Co Ltd
BlueWillow Biologics Inc
Brandenburg Antiinfektiva GmbH
BunyaVax BV
CEL-SCI Corp
Changchun Bcht Biotechnology Co Ltd
Chicago Biosolutions Inc
CHO Pharma Inc
Cidara Therapeutics Inc
Cilian AG
Cocrystal Pharma Inc
Curevac AG
Cytocom Inc
Dnarx LLC
Emergent BioSolutions Inc
Ena Therapeutics Pty Ltd
EpiVax Inc
Etubics Corp
FluGen Inc
Gamma Vaccines Pty Ltd
Genentech Inc
GlaxoSmithKline Plc
Greffex Inc
i2 Pharmaceuticals Inc
ILiAD Biotechnologies LLC
Imutex Ltd
Inovio Pharmaceuticals Inc
InvVax Inc
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Mayly Life Sciences
Medicago Inc
Microbiotix Inc
NanoViricides Inc
New Amsterdam Sciences Inc
Novavax Inc
PeptiDream Inc
Pneumagen Ltd
Recce Ltd
Sanofi Pasteur SA
Sciogen Inc
Seqirus Ltd
Serum Institute of India Ltd
TechnoVax Inc
Tiba Biotech LLC
Touchlight Genetics Ltd
UMN Pharma Inc
Vaccibody AS
Vacthera BioTech GmbH
Vaxart Inc
Vaxxas Pty Ltd
Viramatix Sdn Bhd
Virion Biotherapeutics
Vironova Medical AB
Virvio Inc
Visterra Inc
Vivaldi Biosciences Inc